StreetAlpha.app
Home › Stocks › RAPP

Rapport Therapeutics, Inc. (RAPP)

Healthcare
$23.76
▼ −4.27%
LAST CLOSE · NOV 17

Rapport Therapeutics develops small molecule drugs for neurological and psychiatric disorders, led by a candidate for focal onset seizures. It last closed at $23.76 on Nov 17, down 4.27% on the day. The average 12-month price target from 6 analysts is $64.00 (+169.4% from the last close), with a high of $82.00 and a low of $47.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $2.1M, the largest $1.2M.

AI Auto Pilots
Is RAPP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$150.5M
EPS (diluted)
−$3.17
Free cash flow
−$121.2M
Valuation
Market cap
$1.4B
59.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$74.8M
At Sep 30
Shareholder equity
$391.2M
Shares outstanding
59.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$34.8M−$34.8MFY2023FY2024: −$78.3M−$78.3MFY2024FY2025: −$111.5M−$111.5MFY2025

From RAPP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on RAPP in the past 90 days
Average 12-month target
$64.00
▲ 169.4% upside

Based on 6 analysts who set a price target on RAPP in the past 90 days. The average target is $64.00, with a high of $82.00 and a low of $47.00, compared with the last close of $23.76.

Low $47.00Avg $64.00High $82.00
Blue marker: last close $23.76
Highest target$82.00
Average target$64.00
Lowest target$47.00
Latest rating changes
UBSTarget lowered
Nov 6Buy$71 → $64
GuggenheimTarget lowered
Nov 5Buy$70 → $66
Wells FargoTarget lowered
Nov 5Buy$50 → $47
Jones TradingMaintained
Oct 21Buy$82
Wells FargoMaintained
Oct 21Buy$50
DateFirmActionRatingPrice target
Nov 6UBSTarget loweredBuy$71 → $64
Nov 5GuggenheimTarget loweredBuy$70 → $66
Nov 5Wells FargoTarget loweredBuy$50 → $47
Oct 21Jones TradingMaintainedBuy$82
Oct 21Wells FargoMaintainedBuy$50
Loading…

Technical Analysis

RAPP · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 31% below its 50 day average. It is 50% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38). The nearest support is the Pivot S1 at $23.19, and the nearest resistance the Pivot at $23.98.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.4%/day
Key levels
$52.9352 week high+122.8%
$37.74100 day average+58.8%
$35.56200 day average+49.7%
$31.0650 day average+30.7%
$26.36Swing high (Nov 4)+10.9%
$25.3220 day average+6.6%
$24.55Pivot R1+3.3%
$23.98Pivot+0.9%
$23.76Last close
$23.19Pivot S1−2.4%
$22.95Swing low (Nov 6)−3.4%
$22.0652 week low−7.2%
Indicators
RSI (14)38.45Weak, oversold below 30Neutral
MACD-1.60Above its signal lineBullish
Stochastic49.1Middle of its rangeNeutral
ADX (14)30.5Trending down
Williams %R-72.8Oversold below −80, overbought above −20Neutral
CCI (20)-107.2Oversold below −100, overbought above 100Oversold
Rate of change−6.6%Change over 10 sessionsBearish
ATR (14)$2.01Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RAPP

What happened before

See how RAPP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in RAPP in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$2.1M
Largest print
$1.2M
Loading…

RAPP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲89 buying vs 65 selling
  • ▼Held by funds -1.5 pts
  • ▲Funds holding +9
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding170161+5.6%
In funds' top 1067−14.3%
Held by funds85.0%86.5%−1.5 pts
New / increased31 / 5826 / 56+8.5%
Reduced / sold out41 / 2446 / 12+12.1%
Put/call ratio2.17––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RAPP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RAPP is in one of them and how their past RAPP trades turned out.

RAPP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RAPP in an article yet. Here's the latest on the wider market.

About Rapport Therapeutics

Rapport Therapeutics is a biotechnology company based in Boston, Massachusetts, that develops small molecule drugs for neurological and psychiatric disorders. Its lead candidate, RAP-219, is being studied for focal onset seizures, a form of epilepsy, and is also being evaluated for generalized seizures and bipolar mania. The company is also developing an injectable version of that candidate and earlier-stage programs aimed at chronic pain, migraine, and hearing and balance disorders. Its intended market is patients with these conditions and the physicians who treat them.

Headquarters
Boston, MA